FY2026 EPS Estimate for Globus Medical Increased by Analyst

Globus Medical, Inc. (NYSE:GMED) – Equities researchers at Zacks Research raised their FY2026 EPS estimates for shares of Globus Medical in a note issued to investors on Tuesday, March 10th. Zacks Research analyst Team now forecasts that the medical device company will earn $4.40 per share for the year, up from their prior forecast of $3.85. Zacks Research currently has a “Strong-Buy” rating on the stock. The consensus estimate for Globus Medical’s current full-year earnings is $3.44 per share. Zacks Research also issued estimates for Globus Medical’s Q4 2026 earnings at $1.37 EPS, Q1 2027 earnings at $1.07 EPS, Q2 2027 earnings at $1.14 EPS, Q3 2027 earnings at $1.21 EPS and FY2027 earnings at $4.66 EPS.

GMED has been the topic of several other research reports. Morgan Stanley upped their price target on Globus Medical from $70.00 to $100.00 and gave the stock an “overweight” rating in a research note on Tuesday, December 2nd. Barclays boosted their target price on Globus Medical from $118.00 to $123.00 and gave the stock an “overweight” rating in a report on Wednesday, February 25th. Royal Bank Of Canada increased their target price on Globus Medical from $92.00 to $100.00 and gave the stock an “outperform” rating in a research note on Wednesday, December 17th. Canaccord Genuity Group raised their price target on Globus Medical from $105.00 to $112.00 and gave the company a “buy” rating in a report on Friday, January 9th. Finally, TD Cowen raised Globus Medical to a “strong-buy” rating in a research report on Tuesday, January 27th. Two analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and five have given a Hold rating to the stock. Based on data from MarketBeat, Globus Medical has an average rating of “Moderate Buy” and an average price target of $104.36.

Globus Medical Stock Performance

GMED stock opened at $87.22 on Thursday. The firm has a 50 day moving average price of $90.82 and a 200-day moving average price of $78.05. Globus Medical has a 52-week low of $51.79 and a 52-week high of $101.40. The firm has a market capitalization of $11.80 billion, a price-to-earnings ratio of 22.14, a PEG ratio of 2.02 and a beta of 1.05.

Globus Medical (NYSE:GMED) last posted its quarterly earnings data on Tuesday, February 24th. The medical device company reported $1.28 EPS for the quarter, topping the consensus estimate of $1.06 by $0.22. The business had revenue of $826.42 million for the quarter, compared to analyst estimates of $803.29 million. Globus Medical had a net margin of 18.30% and a return on equity of 12.57%. Globus Medical’s quarterly revenue was up 25.7% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.84 earnings per share.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in GMED. Invesco Ltd. lifted its holdings in shares of Globus Medical by 1,235.2% during the 4th quarter. Invesco Ltd. now owns 3,886,405 shares of the medical device company’s stock valued at $339,322,000 after buying an additional 3,595,339 shares during the period. Burgundy Asset Management Ltd. increased its position in Globus Medical by 24.3% during the second quarter. Burgundy Asset Management Ltd. now owns 3,481,438 shares of the medical device company’s stock valued at $205,474,000 after acquiring an additional 679,691 shares during the last quarter. Bank of Montreal Can lifted its holdings in Globus Medical by 15,317.1% in the fourth quarter. Bank of Montreal Can now owns 3,373,260 shares of the medical device company’s stock valued at $294,519,000 after acquiring an additional 3,351,380 shares during the period. William Blair Investment Management LLC lifted its holdings in Globus Medical by 17.2% in the third quarter. William Blair Investment Management LLC now owns 2,819,165 shares of the medical device company’s stock valued at $161,454,000 after acquiring an additional 414,134 shares during the period. Finally, Sculptor Capital LP boosted its position in Globus Medical by 31.9% in the second quarter. Sculptor Capital LP now owns 2,760,688 shares of the medical device company’s stock worth $162,936,000 after purchasing an additional 667,850 shares during the last quarter. Institutional investors own 95.16% of the company’s stock.

Insider Buying and Selling at Globus Medical

In other news, CFO Kyle Kline sold 3,594 shares of the company’s stock in a transaction on Thursday, January 8th. The stock was sold at an average price of $101.10, for a total transaction of $363,353.40. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Leslie V. Norwalk sold 2,000 shares of the stock in a transaction on Thursday, January 8th. The shares were sold at an average price of $101.10, for a total value of $202,200.00. Following the sale, the director directly owned 10,419 shares in the company, valued at $1,053,360.90. This trade represents a 16.10% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders have sold 35,594 shares of company stock worth $3,332,253. Insiders own 18.51% of the company’s stock.

Key Headlines Impacting Globus Medical

Here are the key news stories impacting Globus Medical this week:

• Positive Sentiment: Zacks Research raised EPS estimates across Q1–Q4 (2026–2027) and issued an FY2028 projection of $5.18, maintaining a “Strong‑Buy” rating — this boosts earnings credibility and upside expectations.
• Positive Sentiment: Short interest dropped ~30% in February to ~3.27M shares (≈3.0% of float), lowering potential selling pressure and shortening the days‑to‑cover to about 2.3 days — a constructive technical development.
• Positive Sentiment: Q4 results and Nevro update refreshed the investment story: Q4 revenue and EPS beats support the raised estimates and near‑term momentum. How The Globus Medical (GMED) Investment Story Is Evolving After Q4 Results And Nevro Update
• Positive Sentiment: GMED was included in a Zacks list of 5 medical instruments stocks with short‑term upside, highlighting favorable analyst attention and thematic tailwinds (AI, M&A, product pipeline). 5 Medical Instruments Stocks to Buy Amid Huge Short-Term Price Upside
• Neutral Sentiment: The company reaffirmed its 2026 outlook, prompting discussion about capital allocation priorities (share repurchases vs. M&A/investment) — signals stability but decisions will drive long‑term allocation impact. Does Globus Medical’s (GMED) Reaffirmed 2026 Outlook Reveal Its Next Capital Allocation Priorities?
• Neutral Sentiment: Analysts and value models are reassessing fair value after recent share weakness—this has generated more coverage and volatility but not new negative company fundamentals. Assessing Globus Medical (GMED) After Recent Share Price Weakness And Fair Value Signals

About Globus Medical

Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.